Santarus and Cosmo's colitis drug meets Phase III trial's key goal

09/29/2010 | Reuters

A Phase III study found that Santarus and Cosmo Pharmaceuticals' budesonide MMX worked better than a dummy pill at putting patients with mild or moderate active ulcerative colitis in remission after eight weeks. Both 9- and 6-milligram doses of the treatment were well tolerated, the drugmakers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD